Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-02545920 open-label extension in Huntington's disease
2014-004900-31Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mardepodect in Huntington disease (HD), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability. Started Feb 2015; status: terminated.
02
Drugs
mardepodect
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2014-004900-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004900-31.